Displaying 51 - 60 of 64 results
-
Applying for specify brand advice statusUse this application form to apply for a new or changed specify brand advice listing.
-
Safe Medication Management newsletters - 2010Newsletters from the SMM programme for the year 2010
-
ALERT 4: Error-prone abbreviations, symbols and dose designations NOT TO USETo eliminate the risk associated with the use of error-prone abbreviations, symbols and dose designations when communicating any type of medicine-related information verbally, handwritten, pre-printed or electronically.
-
ALERT: MetoprololThis alert highlights recommended actions to reduce the risk in adults of 118.75mg oral metoprolol being administered when metoprolol 11.875mg is prescribed.
-
Safe use of opioids collaborative information for DHB hospitalsInformation document for DHBs about the breakthrough series collaborative on safe use of opioids in hospitals.
-
Safe use of opioids measurement: frequently asked questionsFrequently asked questions about measurement for the safe use of opioids.
-
Opioid implementation packageThis package outlines the next steps and what the options are to make a significant difference in opioid-induced adverse drug events.
-
Acetylcysteine for the treatment of paracetamol overdose and toxicity – 2-bag dosing guidanceNew dosing guidance for acetylcysteine for the treatment of paracetamol overdose and toxicity issued in January 2019.
-
Safety Signal: Changes to the labelling of Bicillin LA®Following international practice, the name and strength description for Bicillin LA® has been changed. The expression of the name will now be benzathine benzylpenicillin tetrahydrate. The expression of product strength will now be 1,200,000 units/2.3
-
Display of combination product medicines in electronic systemsGuidelines for the display of combination product medicines in electronic systems.